| Pharma CDMO | Custom synthesis, process R&D, scale-up, and manufacturing of drug intermediates, APIs, ADC payloads, oligonucleotides, and formulations. | Deep chemistry expertise, US FDA approved facilities, strategic partnerships, unique payload-linker IP, and diversified modality portfolio. | Primarily B2B focused on global pharmaceutical innovators and biotech companies developing new chemical entities and advanced modalities. | High-potency APIs, ADC payloads, oligonucleotide building blocks, and specialized custom synthesis services. | 737 | 62 | Project contracts, long-term manufacturing agreements, and licensing revenue from global pharma and biotech clients. | Mix of fixed contracts, milestone payments, and long-term supply agreements; pricing reflects technical complexity and regulatory compliance. | New modality platforms, increased RFP inflow, expansion of ADC and oligonucleotide pipelines, and innovator partnerships drive growth. | Pharma CDMO services |
| Specialty Chemicals | Oligonucleotide building blocks, nucleic acid derivatives, agrochemicals, and performance chemicals including OLED intermediates. | Strong R&D, backward integration, industry certifications, and exclusive partnerships in niche chemistry domains. | Agrochemical, electronic chemical, and specialty chemical innovators primarily B2B, focusing on Japan, Europe, and US markets. | High-purity electronic chemicals and advanced agrochemical intermediates. | 204 | 17 | Contract manufacturing and development services for specialty chemical innovators and agrochemical companies. | Contractual and project-based pricing with focus on high-purity complex chemistry and backward integration for cost advantage. | Recovery in agrochemical cycles, new Japanese partnerships, and specialty chemical demand in electronics coatings. | Sapala Organics |
| API+ (Active Pharmaceutical Ingredients and Formulations) | Development and manufacturing of NCE-based API intermediates, formulations, and controlled substances with regulatory approvals. | Regulatory compliance, existing multi-year contracts, extensive in-house R&D and manufacturing capabilities. | Global pharmaceutical companies requiring complex APIs and contract manufacturing of formulations, B2B model. | Specialty and controlled substance APIs, ANDA filings, and regulated market supplies. | 276 | 21 | Sales from API and formulation supplies to pharma companies, regulatory filings, and licensing income. | Sales contracts with volume commitments, milestone-based licensing fees, and tiered pricing for regulated markets. | New product validations, US and EU filings, formulation launches, and backward integration efforts. | Casper Pharma, Controlled Substance APIs |
